Lilly to launch multi-dose weight-loss drug device in US

Feb 23 (Reuters) - Eli ‌Lilly said ​on ​Monday it received the U.S. Food and Drug Administration's approval to ‌launch a four-dose KwikPen for its weight-loss ⁠drug Zepbound, delivering a full month of the ‌treatment in a single ‌device.

Rival Novo Nordisk's Wegovy has been sold as a single-dose weekly autoinjector pen ​for weight loss in the U.S. since 2021.

Here are some details:

* Zepbound KwikPen ⁠will be available starting at $299 per month for the 2.5-milligram ​dose for cash-paying customers

* The multi-dose injection pen will be available in ​all six doses - 2.5 mg, ‌5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg

* ⁠KwikPen is also used to deliver Lilly's diabetes drug Mounjaro

* The device is available in ⁠many major international regions such as the United ​Kingdom, Australia, the Middle East and Canada

* Zepbound, approved by the FDA in 2023, is also available ‌as a single-dose autoinjector or in vials in the U.S.

* It ‌has overtaken Novo Nordisk's Wegovy as the ⁠weight-loss market leader ‌in the U.S., ​based on prescription data

(Reporting by Christy Santhosh in Bengaluru; Editing by Sriraj ‌Kalluvila)

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
• Bank of America lifts tobacco estimates after regulatory wins
• /C O R R E C T I O N -- Eli Lilly and Company/